MX2023011853A - Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. - Google Patents
Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer.Info
- Publication number
- MX2023011853A MX2023011853A MX2023011853A MX2023011853A MX2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- prmt5
- cancer
- treatment
- methyl transferase
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title abstract 3
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title 2
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172643P | 2021-04-08 | 2021-04-08 | |
| US202163253029P | 2021-10-06 | 2021-10-06 | |
| PCT/US2022/023388 WO2022216645A1 (en) | 2021-04-08 | 2022-04-05 | Combination therapies using prmt5 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011853A true MX2023011853A (es) | 2023-12-07 |
Family
ID=81748438
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011853A MX2023011853A (es) | 2021-04-08 | 2022-04-05 | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12171765B2 (https=) |
| EP (1) | EP4319753A1 (https=) |
| JP (1) | JP2024513494A (https=) |
| KR (1) | KR20230167050A (https=) |
| AU (1) | AU2022254651A1 (https=) |
| CA (1) | CA3214535A1 (https=) |
| IL (1) | IL307393A (https=) |
| MX (1) | MX2023011853A (https=) |
| WO (1) | WO2022216645A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240208912A1 (en) * | 2021-03-11 | 2024-06-27 | Mirati Therapeutics, Inc. | MTA-Cooperative PRMT5 Inhibitors |
| WO2023098439A1 (zh) * | 2021-11-30 | 2023-06-08 | 上海和誉生物医药科技有限公司 | 一种吡唑衍生物，其制备方法和在药学上的应用 |
| WO2023125540A1 (zh) * | 2021-12-27 | 2023-07-06 | 南京明德新药研发有限公司 | 吡唑-1(2h)-酞嗪酮类化合物及其应用 |
| CN119301101A (zh) * | 2022-07-29 | 2025-01-10 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
| WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
| CN120265615A (zh) * | 2022-11-29 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪的化合物 |
| WO2024177416A1 (ko) * | 2023-02-22 | 2024-08-29 | 단국대학교 천안캠퍼스 산학협력단 | Egfr 표적치료제 내성암 치료용 약학 조성물 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025157288A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3268044A2 (en) * | 2015-03-11 | 2018-01-17 | The Broad Institute Inc. | Prmt5 inhibitors for the treatment of cancer with reduced mtap activty |
| JP2021176819A (ja) | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | キナゾリン化合物を有効成分とする医薬組成物 |
| IL290341B2 (en) | 2019-09-12 | 2024-11-01 | Mirati Therapeutics Inc | Mta-cooperative prmt5 inhibitors |
| KR20220086628A (ko) * | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
-
2022
- 2022-04-05 EP EP22724161.9A patent/EP4319753A1/en active Pending
- 2022-04-05 CA CA3214535A patent/CA3214535A1/en active Pending
- 2022-04-05 IL IL307393A patent/IL307393A/en unknown
- 2022-04-05 AU AU2022254651A patent/AU2022254651A1/en active Pending
- 2022-04-05 WO PCT/US2022/023388 patent/WO2022216645A1/en not_active Ceased
- 2022-04-05 KR KR1020237035696A patent/KR20230167050A/ko active Pending
- 2022-04-05 JP JP2023561863A patent/JP2024513494A/ja active Pending
- 2022-04-05 MX MX2023011853A patent/MX2023011853A/es unknown
- 2022-04-05 US US17/713,455 patent/US12171765B2/en active Active
-
2024
- 2024-11-19 US US18/951,832 patent/US20250073241A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230167050A (ko) | 2023-12-07 |
| US20250073241A1 (en) | 2025-03-06 |
| JP2024513494A (ja) | 2024-03-25 |
| AU2022254651A1 (en) | 2023-11-02 |
| EP4319753A1 (en) | 2024-02-14 |
| CA3214535A1 (en) | 2022-10-13 |
| IL307393A (en) | 2023-12-01 |
| US20220331323A1 (en) | 2022-10-20 |
| US12171765B2 (en) | 2024-12-24 |
| WO2022216645A1 (en) | 2022-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011853A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| GEAP202516803A (en) | Bicyclic amines as cdk2 inhibitors | |
| BR112021024999A2 (pt) | Inibidores de prmt5 | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2016016115A (es) | Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr). | |
| BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
| BR112018002046A2 (pt) | métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
| BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| CO2021001277A2 (es) | Inhibidores de triazol glicolato oxidasa | |
| CY1124688T1 (el) | Θεραπεια πρωτεϊνουριας | |
| BR112021006318A2 (pt) | terapia de combinação para o tratamento de câncer | |
| MX2024004171A (es) | Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer. | |
| CO2024009144A2 (es) | Inhibidores de cinasa met | |
| MX2022004270A (es) | Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2. | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| BR112017022653A2 (pt) | ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph? | |
| MX2021009863A (es) | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. | |
| BR112020019624A8 (pt) | Método para tratar a hipoglicemia pós-prandial | |
| MX2021002652A (es) | Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares. | |
| BR112018073627A2 (pt) | método para tratar câncer em um paciente |